Review Article
J Rheum Dis 2012; 19(1): 4-10
Published online February 29, 2012
© Korean College of Rheumatology
골다공증의 최신 치료
정윤석
아주대학교 의과대학 내분비대사내과학교실
Current and Upcoming Treatments for Osteoporosis
Osteoporosis is a common senile disease that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. Currently, good anti-fracture data supports many available anti-resorptive and anabolic drugs including bisphosphonates, selective estrogen receptor modulators, and recombinant human parathyroid hormones. Calcium and vitamin D are also essential treatments for the prevention and treatment of osteoporosis. Although, bisphosphonate is the cornerstone of osteoporosis treatment and is considered as the first line of therapy, their duration of therapy and long- term safety is under question. Novel agents, particularly denosumab, inhibitors of cathepsin K, andanabolic agents that act on Wnt signaling, will increase the therapeutic options for clinicians in the coming years.
Keywords Osteoporosis, Treatment, Medication
PDF
Standard view
Export citation
Share Article
Review Article
J Rheum Dis 2012; 19(1): 4-10
Published online February 29, 2012
Copyright © Korean College of Rheumatology.
골다공증의 최신 치료
정윤석
아주대학교 의과대학 내분비대사내과학교실
Current and Upcoming Treatments for Osteoporosis
Yoon-Sok Chung
Department of Endocrinology & Metabolism, Ajou University School of Medicine, Suwon, Korea
Abstract
Osteoporosis is a common senile disease that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. Currently, good anti-fracture data supports many available anti-resorptive and anabolic drugs including bisphosphonates, selective estrogen receptor modulators, and recombinant human parathyroid hormones. Calcium and vitamin D are also essential treatments for the prevention and treatment of osteoporosis. Although, bisphosphonate is the cornerstone of osteoporosis treatment and is considered as the first line of therapy, their duration of therapy and long- term safety is under question. Novel agents, particularly denosumab, inhibitors of cathepsin K, andanabolic agents that act on Wnt signaling, will increase the therapeutic options for clinicians in the coming years.
Keywords: Osteoporosis, Treatment, Medication
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung Seo, M.D., Jina Yeo, M.D., Jun Won Park, M.D., Yeon-Ah Lee, M.D., Ph.D., Ju Ho Lee, M.D., Eun Ha Kang, M.D., Ph.D., Seon Mi Ji, M.D., Ph.D., Seong-Ryul Kwon, M.D., Ph.D., Seong-Kyu Kim, M.D., Ph.D., Tae-Jong Kim, M.D., Ph.D., Tae-Hwan Kim, M.D., Ph.D., Hye Won Kim, M.D., Ph.D., Min-Chan Park, M.D., Ph.D., Kichul Shin, M.D., Ph.D., Sang-Hoon Lee, M.D., Ph.D., Eun Young Lee, M.D., Ph.D., Hoon Suk Cha, M.D., Ph.D., Seung Cheol Shim, M.D., Ph.D., Youngim Yoon, RN, Seung Ho Lee, Jun Hong Lim, Han Joo Baek, M.D., Ph.D.; on behalf of the Korean Society of Spondyloarthritis Research
J Rheum Dis 2023; 30(3): 151-169 -
Korean guidelines for the management of gout
Jennifer Jooha Lee, M.D., Ph.D., Ji Soo Lee, M.D., Ph.D., Min Kyung Chung, M.D., Ph.D., Joong Kyong Ahn, M.D., Ph.D., Hyo-Jin Choi, M.D., Ph.D., Seung-Jae Hong, M.D., Ph.D., Chong-Hyeon Yoon, M.D., Ph.D., Su-Hyun Kim, M.D., Ph.D., Kyung-Hwan Jeong, M.D., Ph.D., Jong-Woo Kim, M.D., Bo-Yeon Kim, M.D., Ph.D., Jin-Ho Shin, M.D., Ph.D., Woo Gyu Kim, M.D., Soo-Young Kim, M.D., Ph.D., Hyun-Jung Kim, Ph.D., Jeong-Soo Song, M.D., Ph.D., Jae-Bum Jun, M.D., Ph.D., Hyun-Ah Park, M.D., Ph.D., Shung Chull Chae, M.D., Ph.D., Bum Soon Choi, M.D., Ph.D., Tae Nyun Kim, M.D., Ph.D., Hyun Ah Kim, M.D., Ph.D.
J Rheum Dis 2023; 30(3): 141-150 -
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
Joong Kyong Ahn, M.D., Ph.D.
J Rheum Dis 2023; 30(2): 88-98
